IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
Terms of Agreement
Triad 2004 Protein kinase Acquired rights to this program from Triad
for the development of drugs to treat
inflammatory disease. Triad may get up to
$66 m in development and regulatory
milestone payments and sales-based
royalties on products.
Syngene (Biocon, India) 2004 Chemistry Contract research agreement in areas of
synthetic chemistry, molecular biology and
custom synthesis.
Cellzome 2004 Drug discovery Equity investment and 2 years research
funding with 2-yr extension option
developing protein targets in various
diseases. Both companies retain
development options of leads for
license/milestone/ royalty fees. Agreement
extended three times, until June 2008.
Harvard University, the
Massachusetts Institute of
Technology, the Broad
Institute
2004 Diabetes research Novartis spending $4m in public/private
collaboration to fund diabetes research to
uncover genetic basis for type II diabetes.
Xenon Pharmaceuticals 2004 Drug discovery
(metabolic disorders)
ParAllele BioScience 2004 Drug discovery
(coronary artery
disease)
© 2009 IMS Health In cor po rated or its af fil i ates Page 136
$157m 2-yr deal to develop
anti-obesity/metabolic drugs focusing on
Xenon’s SCD1 project with small
molecules in preclinical trials. Xenon
retains rights in some markets while
Novartis to make equity investment and
pay royalties.
ParAllele’s Mismatch Repair Detection
technology to identify new SNPs (single
nucleotide polymorphisms) in (Novartis
selected) genes to be profiled against
coronary artery disease patients to identify
associations. Novartis to use in drug
discovery while ParAllele to retain
diagnostic rights.